Table 1.
Exclusion criteria specific to the MsFLASH 3 by 2 factorial intervention trial
Criterion | Intervention Arm | Rationale |
---|---|---|
Body mass index >37 | Exercise | Rapid progression of exercise prescription not appropriate for heavier women |
Severe uncorrected hearing or vision problems. | Yoga | Need to hear and see yoga instructor |
Current, regular use (≥3 times/week) of anti-coagulants | Omega-3 | Potential omega-3 supplement interaction |
Physical limitations, such as severely limited mobility, severe, recent or chronic back problems, and other musculoskeletal problems that limit the ability to walk on a treadmill or ride a stationary bicycle. | Exercise, yoga | Safety considerations and ensure ability to participate in yoga or exercise interventions, as designed |
Presence of any absolute contraindications to exercise testing and training, as defined by the American College of Sports Medicinea | Exercise | Safety considerations |
Practiced or attended yoga, tai chi, qi gong, or meditation more than one time per week on average in prior 3 months | Yoga | Maximize potential effect of yoga intervention |
Participate in aerobic exercise more than 30 minutes a day on 3 or more days per week in prior 3 months | Exercise | Maximize potential effect of exercise intervention |
Inability to achieve 85% of heart rate reserve (HRR) on graded exercise treadmill test. | Exercise | Provide standard measure of fitness and ensure ability to comply with exercise prescription |
Allergy or sensitivity to fish | Omega-3 | Contents of omega-3 supplement |
Severe allergy to soy | Omega-3 | Contents of omega-3 supplement |
Currently eating 4 or more servings of fish per week. | Omega-3 | Maximize potential effect of omega-3 |
Currently taking an omega-3 fish oil supplement and unwilling to stop | Omega-3 | Maximize potential effect of omega-3 |
absolute contraindications include resting ECG evidence of significant ischemia, unstable angina, and uncntrolled cardiac dysrhythmias; for complete list of absolute and relative contraindications, see Reference #24